Jingsong Wang, MD, PhD
Chief Executive Officer
Dr. Jingsong Wang is the CEO of Harbour Biomed (HBM). Before founding HBM, he was the Head of China Research and Development Center and the Head of Translational Medicine, Asia Pacific, Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles with increasing responsibilities, including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for multiple pre-clinical and clinical assets.
Dr. Wang completed his Clinical Rheumatology Fellowship and subsequently was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang received his PhD in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher's laboratory at the Harvard School of Public Health.
Dr. Wang is an Adjunct Assistant Professor of Medicine at the University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China, and as a scientific grant reviewer for the Medical Research Council, National Institute for Health Research, National Health Service of the United Kingdom.
Xiaoxiang Chen, MD
Executive Vice President, Head of Clinical Development and Regulatory Science
Dr. Chen brings to Harbour BioMed more than 20 years of leadership experience in regional and global clinical development, most recently as Boehringer Ingelheim's Vice President, Regional Medical Management for Emerging Markets.
During his career, Dr. Chen has led the successful clinical development and registration into the China market of more than 20 global innovative products across multiple therapeutic areas, including etanercept, tigecycline, venlafaxine, afatinib, nintedanib, dabigatran, linagliptin and empagliflozin.
In his role as Medical Lead for Emerging Markets at Boehringer Ingelheim, Dr. Chen had overall medical responsibilities, including clinical development, in more than 80 countries and regions, including China, Taiwan, Hong Kong, South Eastern Asia, India, the Middle East and Africa. Previously, he served as Boehringer Ingelheim's Vice President, Head of Medicine Development of Greater China. Prior to Boehringer Ingelheim, Dr. Chen served as Director, Clinical Research & Development Organization of Wyeth Asia Pacific, until Global Medical Monitor for chronic pain and infections. Dr. Chen received his Medical Degree from Nanjing Medical University.
Mai-Jing Liao, PhD
Senior Vice President, Head of Business Development and Portfolio Management
Dr. Mai-Jing Liao is the Head of Business Development and Portfolio Management at Harbour BioMed (HBM). Prior to joining HBM, Dr. Liao was at Xian Janssen Pharmaceutical Ltd. where he served in multiple roles with increasing responsibilities in Marketing, Strategic Marketing and Business Development. He joined J&J's Centocor US after receiving his MBA degree from Johnson Graduate School of Management at Cornell University.
Dr. Liao received his PhD degree in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill and was a postdoctoral fellow in Dr. Robert Weinberg's laboratory at Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology (MIT).
George Liu, PhD
Vice President, Head of Early Development and Scientific Operation
Dr. George Liu is the Head of Early Development and Scientific Operation at Harbour BioMed (HBM). Before joining HBM, he was Director of Clinical Pharmacology for Novartis Oncology where he is responsible for clinical pharmacology perspectives of oncology full development and managing early clinical development and life cycle management (LCM) in China. Prior to joining Novartis, Dr. Liu worked at Sanofi, GSK, and Guilford Pharmaceuticals where he held positions with increasing responsibilities for both nonclinical and clinical pharmacokinetics and contributed to the discovery and/or development, including regulatory approval, of Lusedra®, Anoro®, Ellipta®, Insuman, Mozobil, Signifor ®, LEE011, LDK378, and LCI699.
Dr. Liu has over 20 years of pharmaceutical research, development, management and leadership experience in discovery research, bioanalysis, drug metabolism and pharmacokinetics, clinical pharmacology, project and people management in both pharmaceutical and biotech settings. He is a member of Professional Committee of Pharmacometrics of China Phamacological Society; member of DIA Advisor Council of China (ACC) and American Association of Pharmaceutical Scientists (AAPS).
Dr. Liu obtained his BS in Biology from Nanjing University in 1990 and PhD in Medicinal Chemistry and Molecular Pharmacology from the School of Pharmacy and Pharmaceutical Sciences of Purdue University in 1999.
Xiangyang Tan, MD, PhD
Head of Antibody Technologies
Dr. Xiang Yang Tan brings over 20 years of industry experience and leading roles in the discovery and development of antibody therapeutics. He has contributed to R&D efforts that have led to the development of numerous preclinical and clinical candidates at major companies including Biogen, Pfizer, Wyeth, Genetics Institute.
Prior to joining the biopharmaceutical industry, Dr. Tan received his postdoctoral training in hematology and oncology from Harvard Medical School, where he investigated novel immunotherapy strategies for tumors and HIV. He then studied tumor angiogenesis, vascular targeting and tissue-specific drug delivery. He has published over 40 research papers, and claims authorship to over a dozen US and international patents.
Dr. Tan earned his MD from Harbin Medical University in China, and PhD in Cell Biology and Molecular Biology from Manchester Metropolitan University in the United Kingdom.
Yiping Rong, PhD
Head of Discovery Biology
Before joining Harbour BioMed, Dr. Rong was Associate Director of Cancer Research at Sanofi Asia Pacific R&D Center. Prior to that, he was at Johnson & Johnson China Discovery Center, where he was the Group Leader for preclinical translational oncology research, studying cell growth factor signaling pathway and epigenetic regulation in liver cancer. As biology leader, he successfully generated the preclinical data package and patient stratification biomarker strategy to support novel oncology drug IND filing. Before that, Dr. Rong worked at Roche R&D as a group leader for biologics project in Discovery Oncology Department and was also involved in external project evaluation and coordination.
Dr. Rong obtained his Pharmacology PhD from Case Western Reserve University.
Jiuqiao (Joe) Zhao, PhD
Head of External Innovation
Dr. Zhao has twenty years of drug discovery experience in small biotech and large pharmaceutical companies with extensive knowledge in pharmacology, target discovery, target validation, high throughput screening of small molecule compounds, and antibody discovery. Prior to joining Harbour BioMed, Dr. Zhao was a Senior Research Investigator in Bristol-Myer Squibb, focusing on immunotherapy drug discovery. Before that, he was a Research Investigator in Pharmacopeia/Ligand Pharmaceuticals, specializing in small molecule drug discovery against kinase and GPCR targets.
Dr. Zhao received his PhD in Molecular and Cellular Biology from University of Delaware and BS in Genetics from Fudan University.